WO2025242190 - TREATMENT OF TUMORS BY MEANS OF ANTI-TIGIT ANTIBODY IN COMBINATION WITH ANTI-PD-1 ANTIBODY
National phase entry is expected:
Publication Number
WO/2025/242190
Publication Date
27.11.2025
International Application No.
PCT/CN2025/096706
International Filing Date
23.05.2025
Title **
[English]
TREATMENT OF TUMORS BY MEANS OF ANTI-TIGIT ANTIBODY IN COMBINATION WITH ANTI-PD-1 ANTIBODY
[French]
TRAITEMENT DE TUMEURS AU MOYEN D'UN ANTICORPS ANTI-TIGIT EN COMBINAISON AVEC UN ANTICORPS ANTI-PD-1
[Chinese]
抗TIGIT抗体和抗PD-1抗体联合治疗肿瘤
Applicants **
BIO-THERA SOLUTIONS, LTD.
Inventors
CHAO, Chuanqi
WANG, Hao
LI, Shengfeng
Priority Data
202410659012.9
24.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2206 | |
| EPO | Filing, Examination, Granting | 20030 | |
| Japan | Filing, Examination, Granting | 2670 | |
| South Korea | Filing, Examination, Granting | 3136 | |
| USA | Filing, Examination, Granting | 6940 |
Total:
34,982
Contact Us
Abstract[English]
Disclosed in the present invention is the use of an anti-TIGIT antibody or an antigen-binding fragment and an anti-PD-1 antibody or an antigen-binding fragment in the preparation of drugs for treating tumors.[French]
La présente invention concerne l'utilisation d'un anticorps anti-TIGIT ou d'un fragment de liaison à l'antigène et d'un anticorps anti-PD-1 ou d'un fragment de liaison à l'antigène dans la préparation de médicaments pour le traitement de tumeurs.[Chinese]
本发明公开了抗TIGIT抗体或抗原结合片段和抗PD-1抗体或抗原结合片段在制备用于治疗肿瘤的药物中的用途。